عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Interactive Maps Installed at Madinah Book Fair to Enrich Visitors' Experience, Facilitate Searches

The third edition of Madinah Book Fair kicked off on Tuesday in Saudi Arabia. (SPA)
The third edition of Madinah Book Fair kicked off on Tuesday in Saudi Arabia. (SPA)
TT
TT

Interactive Maps Installed at Madinah Book Fair to Enrich Visitors' Experience, Facilitate Searches

The third edition of Madinah Book Fair kicked off on Tuesday in Saudi Arabia. (SPA)
The third edition of Madinah Book Fair kicked off on Tuesday in Saudi Arabia. (SPA)

The Madinah Book Fair integrated modern technologies to facilitate visitors' searches for books, participating publishers, or exhibition areas hosting various activities, the Saudi Press agency said on Thursday.
Through interactive maps, similar to GPS navigation maps, that are installed throughout the fairgrounds, visitors can locate publishers and authors and can also navigate all areas of the fair by scanning Quick Response (QR) codes on their mobile devices, including the main stage, workshop areas, children's zone, book signing platforms, restaurants and cafes, restrooms, prayer areas, and others.
The interactive touch-enabled maps spread throughout the exhibition operate with advanced technology, allowing visitors to search for specific publishers and obtain detailed information such as their names, the booth number where they are located, the distance to reach them, and the estimated time required.

Most Viewed

 
 
Varieties

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
TT
TT

Weight Loss Drug Cut Heart Failure Risk by 38% in Trial

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, US, December 11, 2023. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits.

The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo, according to Reuters.

The trial enrolled 731 patients across 10 countries who have heart failure with preserved ejection fraction and obesity.

The condition "accounts for nearly half of all heart failure cases, and in the US almost 60% of those impacted also live with obesity," Jeff Emmick, Lilly senior vice president, product development, said in a statement.

Lilly said the study also showed the drug significantly improved heart failure symptoms and physical limitations.

Heart failure is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities.

Trial patients on tirzepatide were given weekly injections of the highest dose they could tolerate, up to 15 milligrams, and were followed for a median of two years.

The drug led to 15.7% weight loss in the combined population of people with and without type 2 diabetes, compared with 2.2% for the placebo, Lilly said. For the non-diabetes patients, weight loss was 13.9%.

Zepbound, also sold under the brand name Mounjaro for type 2 diabetes, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.

Lilly said the most common side effects for trial patients on tirzepatide were diarrhea, nausea, constipation and vomiting.

The company said it plans to submit the heart failure results to the US Food and Drug Administration and other regulatory agencies starting later this year. The findings will also be presented at an upcoming medical meeting and submitted to a peer-reviewed journal.

Novo Nordisk has reported data showing its GLP-1 weight loss drug Wegovy reduces heart failure symptoms.